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Background: Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of disability, hospitalization, and
premature mortality. General practice is well placed to diagnose and manage COPD, but there is a significant gap
between evidence and current practice, with a low level of awareness and implementation of clinical practice
guidelines. Under-diagnosis of COPD is a world-wide problem, limiting the benefit that could potentially be
achieved through early intervention strategies such as smoking cessation, dietary advice, and exercise. General
practice is moving towards more structured chronic disease management, and the increasing involvement of
practice nurses in delivering chronic care.
Design: A pragmatic cluster randomised trial will test the hypothesis that intervention by a practice nurse-general
practitioner (GP) team leads to improved health-related quality of life and greater adherence with clinical practice
guidelines for patients with newly-diagnosed COPD, compared with usual care. Forty general practices in greater
metropolitan Sydney Australia will be recruited to identify patients at risk of COPD and invite them to attend a case
finding appointment. Practices will be randomised to deliver either practice nurse-GP partnership care, or usual
care, to patients newly-diagnosed with COPD.
The active intervention will involve the practice nurse and GP working in partnership with the patient in
developing and implementing a care plan involving (as appropriate), smoking cessation, immunisation, pulmonary
rehabilitation, medication review, assessment and correction of inhaler technique, nutritional advice, management
of psycho-social issues, patient education, and management of co-morbidities.
The primary outcome measure is health-related quality of life, assessed with the St George’s Respiratory
Questionnaire 12 months after diagnosis. Secondary outcome measures include validated disease-specific and
general health related quality of life measures, smoking and immunisation status, medications, inhaler technique,
and lung function. Outcomes will be assessed by project officers blinded to patients’ randomization groups.
Discussion: This study will use proven case-finding methods to identify patients with undiagnosed COPD in
general practice, where improved care has the potential for substantial benefit in health and healthcare utilization.
The study provides the capacity to trial a new model of team-based assessment and management of newly
diagnosed COPD in Australian primary care.
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Chronic obstructive pulmonary disease (COPD) is a
leading cause of morbidity and mortality [1], ranked glo-
bally in 2002 as the fifth leading cause of death [2] and
the seventh leading cause of disease burden after ischae-
mic heart disease and stroke. In Australia, COPD is the
fourth leading cause of death for males (4.2% of all
deaths) and the sixth leading cause of death for women
(3.3% of all deaths); it is also a contributory cause of
death in many patients with coronary heart disease or
cancer [3]. In the Burden Of Obstructive Lung Disease
survey (BOLD), the prevalence of airflow limitation
(GOLD Stage II or higher) in Australians aged ≥40 years
was 10.8% [4], whereas the prevalence of doctor-
diagnosed COPD in the same population was 5.9% [5].
Clinically, COPD is characterised by airflow limitation
that is not fully reversible, and is associated with an
enhanced chronic inflammatory response to noxious
particles or gases [6]. Patients typically present with
breathlessness, cough, and sputum production. The
most important cause in developed countries is cigarette
smoking, and up to 50% of smokers may eventually de-
velop clinically significant COPD [7].
Even mild to moderate COPD is associated with
impaired health status [8]. Patients with COPD have
increased healthcare utilisation before diagnosis, raising
the possibility that earlier diagnosis may allow more ra-
tional and directed use of healthcare resources [9]. The
feasibility of a COPD case-finding approach has been
established. For example, in an Australian study in 2007,
20% of patients identified as being at risk of COPD
responded to invitations to be screened and of these
20% had a new diagnosis of COPD on spirometric cri-
teria [10]. This is similar to findings from primary care
studies in other countries [11-13]. For diagnosis of
COPD, spirometry is required [6], and standards have
been developed for the performance of spirometry in
primary care [14]. Practice nurses can feasibly and suc-
cessfully undertake spirometry [13,15]; as for other
health professionals, approximately six hours of training
are required [16].
Clinical practice guidelines have been developed and
disseminated for the diagnosis and management of
COPD [6], including in Australia (COPD-X guidelines)
[17]. Despite the high level evidence for the efficacy of
guidelines-based interventions, the care provided for
patients with COPD in community settings indicates low
levels of awareness and implementation of these guide-
lines [18]. Medication use is often not in accordance
with guidelines [19,20], and a high proportion of patients
prescribed inhalers use them incorrectly [21,22].
Effective treatment for COPD improves symptoms,
prognosis, and quality of life. Smoking cessation is the
most effective measure to reduce progression of thedisease [23]. Because smoking cessation may become
less effective at altering the course of disease in patients
with severe COPD, interventions that target patients
with mild and moderate disease may be more effective
[24]. In the Lung Health Study [25] smokers with early
COPD who were assigned to a smoking cessation inter-
vention had fewer respiratory symptoms after five years
follow-up than those who were not. Smokers diagnosed
with COPD [26] or who are told their ‘lung age’ [27]
may be more likely to cease smoking.
General practice is well placed to diagnose COPD and
provide early intervention and longer-term management
[28,29]. Care planning and a team approach are effective
in the management of chronic disease. Care planning by
general practitioners (GPs) has been shown to improve
the clinical outcomes for other chronic diseases such as
diabetes [30] and asthma [31], but GPs need more sup-
port to develop and implement multidisciplinary care
plans [32,33] Current guidelines recommend the use of
multidisciplinary care plans in the management of
patients with COPD [17].
Practice nurses are increasingly contributing to chronic
disease management. Specialised nurses have contributed
to the care of patients with diabetes and COPD, and there
is evidence of improvements in patient self-care, quality of
life, and satisfaction [34]. A Cochrane review [35] of nurs-
ing outreach programs for COPD found significant gains
in health-related quality of life for patients with moderate
COPD, but the review highlighted the lack of high quality
studies and concluded that further study was required.
While the role of specialist nurses in contributing to the
care of patients with COPD has been examined [35-37]
and some evidence of benefit in disease-specific quality of
life has been found, there are few studies examining
the potential role of practice nurses working in partner-
ship with GPs in providing more coordinated,
integrated, and evidence-based care for patients with newly-
diagnosed COPD.
Study aims
The primary aim is to assess the effectiveness of early
intervention by a GP-nurse team applying evidence-
based guidelines, compared with usual care, in the
assessment and management of patients newly diag-
nosed with COPD. Secondary aims are to assess the ac-
ceptability of the two management approaches to GPs,
nurses and patients, and to assess the utility of the
COPD Diagnostic Questionnaire (CDQ) and COPD
Assessment Test (CAT) in an Australian population.
Study hypothesis
The study hypothesizes that intervention by a GP-
practice nurse team leads to improved health-related
quality of life and greater adherence with clinical
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COPD, compared with usual care.Methods
Study approvals
The PELICAN study (Primary care EarLy Intervention
for Copd mANagement) is a pragmatic cluster rando-
mized controlled study with two treatment arms, which
is being conducted in greater metropolitan Sydney, Aus-
tralia. The study is funded by the National Health and
Medical Research Council of Australia (Project Grant
No. 630421). Ethical approval has been obtained from
the Human Research Ethics Committee, University of
New South Wales (HREC 10015). The project has been
registered with the Australian Clinical Trials Registry
(ACTRN12610000592044).Practice recruitment
Identification of eligible 
patients at risk of COPD 
Randomisation of 
practices













Usual care practices sent 
copy of COPD guidelines
Figure 1 Study and data collection processes.Study design
This pragmatic cluster randomized controlled trial will
test the hypothesis that early intervention by a practice
nurse-GP partnership will improve outcomes for
patients newly diagnosed with COPD, compared with
usual care. Because the intervention involves a team ap-
proach by treating practitioners, randomization will
occur at the practice level rather than at the level of in-
dividual patients (CONSORT guidelines for cluster trials
[38,39]). All participating practices will use case-finding
methods to identify a cohort of patients with newly diag-
nosed COPD.
The research plan, identifying recruitment strategies,
randomization, data collection points, and the relation-
ships between intervention and control groups in
the two arms are summarised in Figure 1. Because it
is a complex intervention with potential for variablention training 
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ation as well as quantitative outcome measures.Inclusion criteria
GPs and practice nurses
Practices will be eligible to participate if they have
computer-based patient records, employ at least one
practice nurse, and have a spirometer. More than one
GP per practice may be involved in the study. Written
informed consent will be obtained from GP(s) and prac-
tice nurse(s).Patients
Patients will be eligible for inclusion if they have
attended the practice at least twice, with at least one
visit in the preceding 12 months, and have risk factors
for COPD (aged 40 to 85, and with a documented his-
tory of smoking). Patients will be excluded if they have a
recorded diagnosis of COPD, are unable to understand
English sufficiently to complete study questionnaires or
procedures, or have cognitive impairment.Randomization and allocation concealment
Practices will be randomized to deliver either a practice
nurse-GP team management approach, or usual care, to
patients with newly-diagnosed COPD. Randomization will
be undertaken after the nurses have completed spirometry
and case-finding training, and before case-management
training for the intervention group. Randomization will be
carried out independently of study and practice staff by a
statistician separate to the study team using a computer-
generated randomization program, with a minimisation al-
gorithm to ensure a balance of practice characteristics that
could potentially affect study outcomes. These characteris-
tics are: practice size, as indicated by the number of prac-
tice nurses (1 or >1); socio-economic status, classified
according to Socio-Economic Indexes for Areas (SEIFA,
[40]) (low: SEIFA 1-5, high: SEIFA 6-10); and participation
by the GP in significant (>6 hours) COPD education activ-
ities within the last six months (yes or no). Allocation con-
cealment will be ensured as group allocation will be
conducted at the same time as randomization. Practices
will be informed about their group allocation by fax.Blinding
Participating GPs, practice nurses and patients will not
be blinded to the true aims of the study, nor to their
randomization group. Project officers, who will collect
study outcome measures, will be blinded to group allo-
cation as will the statistician undertaking the analyses.Recruitment
GP and practice nurse recruitment
Recruitment will be conducted with assistance from
Divisions of General Practice (local organisations of
GPs) in the greater Sydney area. GPs and practice nurses
will be provided with an information sheet and asked to
provide written consent. All practices expressing an
interest in taking part in the project will be visited by an
investigator (SD) to discuss the study, answer questions,
and obtain consent from the GP and practice nurse. Fur-
ther recruitment strategies will include provision of
study information packs at GP and practice nurse work-
shops and conferences, and by email to members of the
Australian Practice Nurses Association.
Intervention and Control Groups: Patient recruitment
For both randomization groups, patient recruitment will
involve three stages:
1. Potentially eligible patients, i.e., those at risk of
COPD (aged 40 to 85, with documented smoking
history) will be identified through a search of the
practice electronic records by research assistants
and practice staff who have no involvement in
patient care.
2. Eligible patients will be recruited by a letter from the
practice inviting them to a case-finding visit and
management of COPD, if diagnosed. The letter will
include a brief description of the research and an
invitation to participate, and a response form and
reply-paid envelope. Non-responders will be followed
up by GP practice staff by telephone.
3. Patients who contact the practice in response to the
letter will be given an appointment for the
case-finding visit with the practice nurse. The
consent form will be signed at the start of the
case-finding visit.
For eligible patients who decline to participate in a
case-finding visit, basic de-identified information (age,
gender, language spoken) will be collected from the
practice to allow examination of response bias.
Training of GPs and practice nurses
Intervention and Control Groups—case-finding training of
practice nurses for diagnosis of COPD
All practice nurses, before randomization, will receive
training in case-finding for diagnosis of COPD. For prac-
tice nurses, this comprises a full-day workshop covering
the case-finding approach to diagnosis of COPD, and an
evening follow-up workshop approximately two weeks
later. Because spirometry is essential to the accurate
diagnosis and assessment of COPD [6], detailed training
in the performance and interpretation of spirometry will
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Thoracic Society and the European Respiratory Society
(ATS/ERS) lung function guidelines of 2005 [41,42].
Nurses will receive practical training on their practice’s
own spirometer, and calibration of each spirometer will
be checked during the workshop. The follow-up work-
shop will include revision of spirometry and the pro-
cesses for the case-finding appointment.
Intervention Group only—training in GP-nurse team
management of newly-diagnosed COPD
In practices randomized to the GP-practice nurse part-
nership management arm, the nurses and GPs will at-
tend further workshops to receive practical training in
team-based management of COPD. These additional
workshops for GPs and practice nurses in the GP-
practice nurse partnership intervention will be provided
by the study team including a nurse academic, a GP aca-
demic, and a respiratory physician. The intervention
workshops will comprise a full day for practice nurses, a
distance learning activity for GPs, and an evening work-
shop for both practice nurses and GPs.
The one-day training workshop for nurses will cover:
pathophysiology and assessment of COPD; smoking ces-
sation including use of lung age as a motivational tool
[27]; COPD management according to Australian guide-
lines [17]; prescribing guidelines; assessment of patients’
inhaler technique and education to improve technique
[43]; the role of pulmonary rehabilitation; the manage-
ment of exacerbations; the use and value of nurse/GP
joint care planning; information about reimbursement
codes for relevant activities; and education about self-
efficacy theory, motivation, change management, team-
work, and fostering partnerships. The program will be
based on that used in an earlier study [44], with adapta-
tion to address specific issues for patients with newly-
diagnosed COPD. It will foster a culture of positive
organisational change through team building and pro-
motion of collaborative practice [45]. Practice nurses will
be provided with a folder containing workshop notes
and presentations.
GPs will complete a computer-based distance learning
activity and quiz on the management of COPD accord-
ing to the COPDX guidelines. The evening three-hour
workshop for GPs and practice nurses will focus on the
importance for each GP-practice nurse team to clarify
individual elements of their roles, because lack of under-
standing has been shown to be a barrier to collaborative
practice [46,47]. Each practice will be provided with a
copy of current Australian COPD guidelines [17].
Control group training
After case-finding training, practices that are rando-
mized to usual care will be provided with a print copy ofthe Australian COPD guidelines [17]. At the end of the
study, after conclusion of all data collection for all prac-
tices, GPs and practice nurses in the control group will
be offered a workshop on assisting patients to optimise
their inhaler technique.
Study procedures
Intervention and Control Groups—case-finding
appointments
At the case-finding visit, the practice nurse will first ob-
tain written informed consent for the case-finding
process and for participation in the study if COPD is
diagnosed; patients will also be asked to consent to re-
lease of their contact details to the project officer for ar-
ranging data collection visits. The practice nurse will
administer a questionnaire including demographic data
and the COPD Diagnosis Questionnaire (CDQ, [48]),
without calculation of the CDQ score, and will perform
spirometry before and after two inhalations of salbuta-
mol. Practice nurses will be provided with a computer-
based toolkit [49] to assist in diagnosis of COPD, which
will be based on post-bronchodilator FEV1/FVC <0.7
[6,17]. The patient consent and demographic/contact
details, spirometry printout, diagnosis, and CDQ re-
sponses will be faxed to the project officer. Quality of all
spirometry traces will be reviewed by one investigator
(AC), and if necessary, feedback or additional training in
spirometry will be provided to the practice nurse, ini-
tially by telephone, with face-to-face support, if needed.
Patients will be included in the study on the basis of the
COPD diagnosis assigned by the nurse and/or GP from
the case-finding spirometry.
All current smokers—irrespective of the results of spir-
ometry or practice randomisation—will be offered smoking
cessation advice and resources at the case-finding visit.
Patients with newly diagnosed COPD will be offered man-
agement and follow-up, as below, according to whether the
practice is in the intervention or control group. If spirom-
etry appears abnormal for other reasons (bronchodilator
reversibility suggesting asthma, or restrictive spirometry),
the patient will be referred to the GP.
Intervention group—delivery of GP-Practice nurse team
management for newly-diagnosed COPD
In the intervention practices, the practice nurse will work
in partnership with the GP and patient to develop a care
plan for patients newly-diagnosed as having COPD. The
workbooks provided during the intervention group train-
ing workshops will prompt the nurse and GP to include
relevant components of the following in the care plan:
1. Smoking cessation: advice based on Smoking
Cessation Guidelines for Australian General
Practice [50].
Bunker et al. Implementation Science 2012, 7:83 Page 6 of 10
http://www.implementationscience.com/content/7/1/832. Immunization: influenza and pneumococcal
vaccination status will be assessed relative to local
guidelines [51], and immunization recommended and
provided where appropriate.
3. Exercise: recommendation about regular exercise for
all patients regardless of COPD severity; patients
with moderate or severe COPD provided with details
of their local pulmonary rehabilitation provider.
4. Medication review: review of current medications
and education about potential future indications for
pharmacotherapy. For patients already using any
inhaler, inhaler technique will be checked using
published checklists [43]. Patients for whom inhaled
medication is indicated will be educated on the
appropriate use of these using established
protocols [43].
5. Nutrition: Advice about diet and exercise and referral
to a dietician if appropriate for overweight or
underweight patients.
6. Psychosocial issues: identification and management
of anxiety and/or depression.
7. Co-morbidities and complications of COPD will be
assessed and managed.
8. Patient education: patients will be provided with
written information about COPD (from Australian
Lung Foundation http://www.lungfoundation.com.
au/) and its management and with information about
local patient support groups which provide
emotional support and self-management information.
The nurse and GP will work in partnership with the
patient to implement care plans using appropriate pre-
scribing, investigations, referral, and follow-up consulta-
tions with the GP, and visits or telephone consultations
with the practice nurse. Patients will be added to a
COPD Register within the practice to facilitate appropri-
ate recall and reminder notifications and monitor patient
progress. This will allow recording of implementation
milestones in patient care plans, outstanding actions,
and review arrangements. The guideline-based care plan
for each patient will seek to optimise management, im-
prove function, prevent deterioration, and enhance pa-
tient knowledge and skills. It may be informal, or may
be documented in line with government-funded reim-
bursement programs for chronic disease care [32].
Control group: usual care for newly-diagnosed COPD
In the control practices, at the completion of the case-
finding visit, the nurse will recommend that patients
with newly-diagnosed COPD should see their GP for
management of the condition. Usual care for the pur-
pose of this study will thus be the normal pattern of care
of COPD by the GP; to ensure that all GPs have access
to current Australian COPD guidelines, they will beprovided with a print copy [17]. All current smokers will
be offered brief smoking cessation advice at the case-
finding visit, regardless of the results of spirometry.
Intervention and control groups: mentoring of
practice nurses
Brief periodic mentoring will be provided to all practice
nurses by experienced registered nurses in order to fa-
cilitate compliance with study processes, to enhance re-
cruitment and retention of patients, and to provide a
standardised framework for responding to questions.
Intervention and control practices will receive similar
levels of spirometry mentoring. Intervention practices
alone will receive mentoring relating to GP-nurse case
management of COPD. Mentoring of intervention and
control practices will be carried out by two different




Once the project officer has received the consent form,
contact details, and spirometry worksheet for a patient,
they will arrange a visit as soon as possible for baseline
assessment, either at the patient’s home or at the GP’s
practice according to patient preference. The project
officer will collect demographic data including age, gen-
der, body mass index, employment status, education,
and country of birth, and data for outcome and process
measures. Further data collection will occur at 6 months
(by telephone and mail) and 12 months (face to face).
Outcome measures—patients
The primary outcome measure will be disease-specific qual-
ity of life assessed by the St George’s Respiratory Question-
naire (SGRQ [52]). Secondary outcome measures include:
patient awareness of COPD diagnosis, COPD Assessment
Test (CAT, a disease specific QOL measure [53]); smoking
status by self-report and from carbon monoxide analysis
(Smokerlyzer, Bedfont Scientific Ltd, Maidstone, UK) and
readiness to quit if applicable; immunisation rates; medi-
cation including appropriate inhaler prescription and ef-
fective inhaler use; referral for pulmonary rehabilitation or
referral for or provision of exercise prescriptions; disease
related knowledge [54]; patient satisfaction; healthcare
utilisation; and lung function. The relationship between
objectives, outcomes, measures, and hypothesis is outlined
in Table 1.
Process measures
At each visit/telephone call, patients will be asked the
number of times they have visited the GP and/or prac-
tice nurse (total, and COPD-related), and the COPD-
related areas addressed. At the end of the study, GPs
Table 1 Relationships between objectives, outcomes, measures and hypotheses
Objective Hypothesis Outcome Measure Visit
To assess the effectiveness
of early intervention by a
GP-practice nurse partnership,
in patients newly identified as
having COPD






Improvement in disease related
quality of life
St George’s Respiratory Questionnaire
(SGRQ) [52]
1,2,3
COPD Assessment Test (CAT) 1,2,3
Improved smoking cessation rates Participation in smoking cessation
program; quit rates (self-report)
1,2,3
Validation of smoking cessation
(where applicable)








Improved prescribing and use of
medications for COPD
Audit of prescribing against
COPD-X guidelines
1,2,3
Inhaler technique score using
published checklists [43]
1,3
Increased referral for pulmonary
rehabilitation
Completion of pulmonary rehabilitation
(self-reported)
1,2,3





Improved general health status General health status question (using
preliminary question from SGRQ) [52].
1,2,3
Slower decline in lung function Post-bronchodilator FEV1 1,3
To assess the acceptability
and feasibility of team-based
vs conventional management
of patients with COPD
Improved team-work between GP
and practice nurse
Collaborative Practice Scale, VAS scale
for team management of COPD
End of study
Barriers and facilitators to
team-work management
of COPD
Process measures relating to GP
and PN visits.
1, 2, 3
Semi-structured interviews with GPs,
PNs, patients
End of study
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the extent to which they practice team-based manage-
ment of COPD, on a visual analogue scale. Practice
nurses and GPs will complete the Collaborative Practice
Scale [55] to assess the ‘interactions between nurses and
GPS that enable the knowledge and skills of both profes-
sionals to synergistically influence patient care’ [55].
Semi-structured interviews at the conclusion of the pro-
ject with the practice nurses, GPs, and patients will exam-
ine satisfaction with the program and will explore the
effects and value of the nurse input into COPD diagnosis
and care, and barriers and facilitators to the team-
management approach. The software package NVivoW will
be used to facilitate coding and exploration of the data.
Reimbursement
The project will provide the following support to partici-
pating practices:
1. Intervention and control practices: Reimbursement
for the practice nurse attendance at the COPD
diagnosis and spirometry workshop (AUD270);
payment for the practice nurse to undertake the
medical record search (AUD500); reimbursement for
practice nurse time for case-finding consultations(AUD38.50 for each appointment, for up to 60
patients per practice); continuing professional
development points for workshop attendance.
2. Intervention group: reimbursement for practice
nurse attendance at the COPD team management
workshop (AUD270); reimbursement for GP
attendance at the team management workshop
(AUD450); category two continuing professional
development points for GPs.
Once a diagnosis of COPD is made, any medical or prac-
tice nurse consultations that are required for clinical man-
agement may be funded through normal practice processes.
Small gifts (food baskets) will be provided to practice
reception staff as thanks for their assistance in making
follow-up telephone calls.
Data analysis
Data collation will be managed using Access, and data
analysis undertaken using the Statistical Package for the
Social Sciences (SPSS) by a statistician blind to group al-
location. Analysis will be by intention to treat, i.e., by
the diagnosis assigned by the practice nurse/GP on the
basis of case-finding spirometry, including patients
whose diagnosis of COPD is not confirmed by the
Bunker et al. Implementation Science 2012, 7:83 Page 8 of 10
http://www.implementationscience.com/content/7/1/83project officer. Intra-cluster (practice) correlation coeffi-
cients will be determined and published for all primary
outcome variables to assist future research.
The effect of the intervention on outcomes measured
on a continuous scale (such as SGRQ score) will be esti-
mated and tested using mixed model analysis of variance
in which time and treatment group will be fixed effects
and GP practice and subject nested within practice will
be random effects. The effect of the intervention on the
dichotomous variables (such as smoking and vaccination
status) will be analysed using generalised estimating
equations with a logistic link and a model structure that
is analogous to that described above.
Sample size calculations
The sample size calculation is based on a minimum clin-
ically important difference for the primary outcome
measure (SGRQ) of 4.0 [52], between subject standard
deviation in SGRQ of 13 in a similar population [54],
intra-cluster correlation coefficient of 0.01, and a result-
ant design effect of 1.09 for a cluster size of 10. With
this design effect, a sample size of 200 patients complet-
ing each arm will provide >80% power to detect a differ-
ence of 4 or greater in SGRQ (calculations in PASS
software). Forty practices will each invite 300 patients to
attend a case-finding appointment, and within each
practice this is expected to produce 12 patients with a
new diagnosis of COPD; loss to follow-up of 20% by
12 months has been assumed. The projected recruitment
rate is derived from the response rate to invitation
(25%), and the yield of new diagnoses (21%) in our re-
cently completed case-finding project [10].
This sample size will also confer 90% power to identify
a doubling of the expected rate of correct inhaler use
(from 20% to 40%) at a significance level of 5% (based
on an ICCC of 0.1, and design effect of 2.1).
Discussion
There is substantial evidence that COPD is under-
diagnosed in the community, and that even once a diag-
nosis of COPD is made, many patients are not managed
according to evidence-based guidelines. By the time the
diagnosis is made, COPD is often far-advanced, limiting
the benefit that could potentially be achieved through
early intervention with strategies such as smoking cessa-
tion, dietary advice, and increased exercise. This study
will use proven case-finding methods in an at-risk popu-
lation to identify new patients with COPD, followed by a
pragmatic cluster randomised study design to test a
novel intervention designed to improve the implementa-
tion of evidence-based guidelines for newly-diagnosed
COPD. Practice nurses and GPs will be trained in prac-
tical strategies for assessing and managing COPD, and in
working as a team in managing patients with chronicdiseases. Elements of the intervention have been piloted
and found to be feasible. The impact of this team-based
approach to COPD management on quality of life will
be compared with usual care using a widely used and
validated tool (SGRQ). Other outcome measures will
evaluate the concordance of patient management with
evidence-based guidelines for management of COPD,
using instruments with demonstrated validity and reli-
ability, which are congruent with the recommendations
of the ERS/ATS Task Force on COPD trials [56]. In
addition, the acceptability of the team management ap-
proach to GPs and practice nurses, and barriers and
facilitators to its implementation, will be evaluated with
structured interviews at study end.
This study targets COPD patients in general practice
where the contact with potential patients with mild and
moderate COPD is greatest, and where improved care
has the potential for substantial health benefit. Because
COPD is a major contributor to the burden of disease in
countries such as Australia, improved care is of great
public health significance. If successful, the trial will pro-
vide a model for care of COPD patients in the commu-
nity that is feasible and sustainable. Publication of the
results of the trial will influence policy and practice on
how care for COPD is provided at a national and inter-
national level.
Sustainability of the intervention
In this pragmatic study, the intervention deliberately
makes use of and augments existing practice structures,
staffing, and approaches to chronic disease management.
While there is potential for nurses to undertake
advanced practice in primary care, this study will not re-
quire practice nurses to work at an advanced practice
level. For this study, the role of the practice nurse is fo-
cussed on patient assessment; counselling; education;
and liaison with medical and allied health colleagues,
using expertise that forms part of the skills base of regis-
tered nurses. The intervention is thus potentially
generalizable and easily transferable.
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